Table 11.
Resources needed by a clinician or medical center for the safe and effective use of lecanemab
| • Clinician skilled in the assessment of cognition to identify individuals with mild cognitive impairment or mild dementia due to Alzheimer’s disease |
| • MRI available for baseline assessment of cerebrovascular pathology and for monitoring of amyloid related imaging abnormalities (ARIA) |
| • Radiologists, neurologists, or other clinicians expert in the identification and interpretation of cerebrovascular lesions and ARIA |
| • Amyloid positron emission tomography or lumbar puncture capability to determine the amyloid status of treatment candidates |
| • Radiologists, nuclear medicine specialists, neurologists, or other specialists skilled in the interpretation of amyloid imaging or neurologist, radiologists, or other clinicians skilled in the conduct of lumbar puncture |
| • Apolipoprotein E genotyping resources |
| • Genetic expertise to counsel patients on the implications of apolipoprotein E genotyping |
| • Expertise in communicating with patients and care partners regarding anticipated benefits, potential harm, and requirements for administration and monitoring while on lecanemab |
| • Infusion settings that can be made available every two weeks to patients receiving therapy |
| • Knowledgeable staff at infusion sites capable of recognizing and managing infusion reactions |
| • Communication channels established between experts interpreting MRIs and clinicians treating patients with lecanemab |
| • Communication channels established between clinicians treating patients with lecanemab and the patient and care partner |
| • Availability of hospital resources including intensive care unit |
| • Expertise in the management of seizures and status epilepticus for patients with severe or serious ARIA |
| • Protocol with standard operating procedures for management of serious and severe ARIA |